Evaluation of plasma antioxidant levels during different phases of illness in adult patients with bipolar disorder

Journal of Biological Regulators and Homeostatic Agents

Volumn 22, Issue 3, 2008, Pages 195-200

  De Berardis, Domenico ^a,b   Conti, C M ^a,b   Campanella, D ^a,b   Carano, A ^a,b,c   Di Giuseppe, B ^b   Valchera, A ^d   Tancredi, L ^d   Serroni, N ^b   Pizzorno, A M ^b   Fulcheri, M ^a   Gambi, F ^a   Sepede, G ^a   Moschetta, F S ^b   Salerno, R M ^a   Ferro, F M ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b G Mazzini Hospital   (Italy)

^c G d'Annunzio University ^*  (Italy)

^d San Giuseppe Clinic   (Italy)

Author keywords

Albumin; Antioxidants; Bilirubin; Bipolar disorder; Control subjects; Depression; Euthymia; Mania; Uric acid

Indexed keywords

ANTIOXIDANT;

ADULT; ARTICLE; BIPOLAR DISORDER; BLOOD; CLASSIFICATION; FEMALE; HUMAN; MALE; METABOLISM; PSYCHOLOGICAL ASPECT;

ADULT; ANTIOXIDANTS; BIPOLAR DISORDER; FEMALE; HUMANS; MALE;

EID: 58949100784     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Foschino Barbara MP, Carpagnano GE, Spahevello A, Cagnazzo MG, Barnes PJ. Inflammation, oxidative stress and systemic effects in mild chronic obstructive pulmonary disease. Int J Immunopathol Pharmacol 2007; 20:753-63.
2. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008; 21:1-26.
3. Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press, 1990.
4. De Berardis D, Campanella D, Matera V, Gambi F, La Rovere R, Sepede G, Grimaldi MR, Pacilli AM, Salerno RM, Ferro FM. Thrombocytopenia during valproic acid treatment in young patients with new-onset bipolar disorder. J Clin Psychopharmacol 2003; 23:451-8. (Pubitemid 37128672)
5. Gambi F, De Berardis D, Campanella D, et al. Retrospective study of C-Reactive protein, cholesterol and high density lipoprotein in major depression: preliminary findings. Eur J Inflamm 2005; 3:127-33.
6. De Berardis D, Campanella D, Gambi F, et al. The role of C-reactive protein in mood disorders. Int J Immunopathol Pharmacol 2006; 19:721-5. (Pubitemid 46145036)
7. De Berardis D, Conti CM, Campanella D, et al. Evaluation of C-reactive protein and total serum cholesterol in adult patients with bipolar disorder. Int J Immunopathol Pharmacol 2008; 21:319-24. (Pubitemid 351988393)
8. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133:429-35. (Pubitemid 9006756)
9. Bech P, Bolwig TG, Kramp P, Rafaelsen OJ. The Bech-Rafaelsen Mania Scale and the Hamilton Depression Scale: evaluation of homogeneity and inter-observer reliability. Acta Psychiatr Scand 1979; 59:420-30. (Pubitemid 9164861)
10. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62.
11. Doumas BT, Watson WA, Biggs HG. Albumin standards and the measurement of serum albumin with bromocresol green. Clin Chim Acta 1971; 31:87-96.
12. Pearlman FC, Lee RTY. Detection and measurement of total bilirubin in serum, with use of surfactants as solubilizing agents. Clin Chem 1974; 20:447-53.
13. Trinder P. Determination of glucose in blood using glucose oxidase-peroxidase system with a non-carçinogenic chromogen. J Clin Pathol 1969; 22:158-61.
14. Terzuoli L, Marinello E, Felici C, Frosi B, Setacci C, Giubbolini M, Porcelli B. Purine bases and atheromatous plaque. Int J Immunopathol Pharmacol 2004; 17:31-3.
15. Reddy R, Keshavan M, Yao JK. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res 2003; 62:205-12. (Pubitemid 36773929)
16. Pae CU, Paik IH, Lee C, Lee SJ, Kim JJ, Lee CU. Decreased plasma antioxidants in schizophrenia. Neuropsychobiology 2004; 50:54-6. (Pubitemid 38721170)
17. Yao JK, Reddy R, van Kammen DP. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res 1998; 80:29-39. (Pubitemid 28370837)
18. Gergerlioglu HS, Savas HA, Bulbul F, Selek S, Uz E, Yumru M. Changes in nitric oxide level and superoxide dismutase activity during antimanic treatment. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:697-702. (Pubitemid 46467046)
19. Amdisen A, Hildebrandt J. Use of lithium in the medically ill. Psychother Psychosom 1988; 49:103-19. (Pubitemid 19004610)
20. Hunter RE, Barrera CM, Dohanich GP, Dunlap WP. Effects of uric acid and caffeine on A1 adenosine receptor binding in developing rat brain. Pharmacol Biochem Behav 1990; 35:791-5. (Pubitemid 20129976)
21. Anumonye A, Reading HW, Knight F, Ashcroft GW. Uric-acid metabolism in manic-depressive illness and during lithium therapy. Lancet 1968; 1:1290-3.
22. Machado-Vieira R, Lara DR, Souza DO, Kapczinski F. Therapeutic efficacy of allopurinol in mania associated with hyperuricemia. J Clin Psychopharmacol 2001; 21:621-2. (Pubitemid 33116667)
23. Lara DR, Belmonte-de-Abreu P, Souza DO. Allopurinol for refractory agression and self-inflicted behaviour. J Psychopharmacol 2000; 14:81-3. (Pubitemid 30156544)
24. Erfurth A, Schmauss M. Perspectives on the therapy of neuropsychiatric diseases with adenosinergic substances. Fortschr Neurol Psychiatry 1995; 63:93-8.
25. Akhondzadeh S, Milajerdi MR, Amini H, Tehrani-Doost M. Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar Disord 2006; 8:485-9. (Pubitemid 44560222)
26. Machado-Vieira R, Lara DR, Souza DO, Kapczinski F. Purinergic dysfunction in mania: an integrative model. Med Hypotheses 2002; 58:297-304. (Pubitemid 34777688)
27. Brundege JM, Dunwiddie TV. Role of adenosine as a modulator of synaptic activity in the central nervous system. Advances in Pharmacol 1997; 39:353-91.